newsfilter
← Earnings
Earnings Releases·

Vaxcyte — Third Quarter 2026 Earnings Summary

  • Net loss widened to $297.1 million for Q3 2026 from $212.8 million in the prior year period, driven by increased R&D ($270.3 million) and G&A expenses ($37.9 million), while cash and investments stood at $2.26 billion as of September 30, 2026.
  • The company raised its pro forma cash balance to approximately $3.4 billion following the October 2026 completion of equity and convertible senior notes offerings, which generated $1.1 billion in net proceeds.
  • VAX-31 adult indication achieved positive topline data in the pivotal OPUS-1 Phase 3 trial, meeting all primary endpoints and demonstrating noninferiority across 28 shared serotypes with PCV20/PCV21, with no serious adverse events related to the vaccine.
  • Future milestones include reporting OPUS-2 and OPUS-3 Phase 3 trial results in H1 2027, submitting a BLA for the adult indication in H1 2028, and expecting infant Phase 2 data for VAX-31 by end of H1 2027.
  • Management appointed Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer in September 2026, while advancing VAX-A1, VAX-24, and VAX-XL candidates in their respective development stages.
Company
VAXCYTE INC
Sector
Healthcare
Industry
Biotechnology